SYLVA GARAGULAKIAN: Open Payments
NPI 1215445770 · NORTHRIDGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,040 in 28 payments from 7 companies in 2025. Trend: 2023 $1,942 · 2024 $1,713 · 2025 $1,040
Food & beverage: $1,040
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $294 |
| Amgen Inc. | 6 | $202 |
| Dexcom, Inc. | 1 | $158 |
| ABBVIE INC. | 2 | $135 |
| Corcept Therapeutics | 1 | $125 |
| Astellas Pharma US Inc | 5 | $100 |
| Exact Sciences Corporation | 1 | $26 |
Products named: DEXCOM G7 GSS (161), REPATHA, MAVYRET, Wegovy, Ozempic, Korlym, Veozah, OTEZLA.
Industry payments across CA — which companies pay providers there.
